Vijay Chiruvolu - 20 Jul 2023 Form 3 Insider Report for Turnstone Biologics Corp. (TSBX)

Role
Int. Chief Technology Officer
Signature
/s/ P. Joseph Campisi, Jr., Attorney-in-Fact
Issuer symbol
TSBX
Transactions as of
20 Jul 2023
Net transactions value
$0
Form type
3
Filing time
20 Jul 2023, 21:49:11 UTC
Previous filing
25 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TSBX Employee Stock Option (Right to Buy) 20 Jul 2023 Common Stock 176,344 $16.53 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One fourth (1/4th) of the shares subject to the option award shall vest on March 20, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney